Lisha Wang, Jiao Qian, Mengyuan Chen, Jiajia Qin, Tianbin Tang, Yilan Wang, Linjie Hu, Sufei Yu
Department of Laboratory Medicine, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, China.
Key Laboratory of System Medicine and Precision Diagnosis and Treatment of Taizhou, Taizhou, China.
Microbiol Spectr. 2025 Jul;13(7):e0201324. doi: 10.1128/spectrum.02013-24. Epub 2025 Mar 25.
Regarding metagenomics next-generation sequencing (mNGS) negative literature, there have been much discussions about methodology; thus, we collected clinical and laboratory information for retrospective evidence-based research. We retrospectively analyzed 150 negative mNGS results of patients suspected of having aseptic body fluid infections and divided them into a plasma group, cerebrospinal fluid (CSF) group, and others group according to the sample types. Based on the final laboratory and clinical diagnoses, the diagnostic accuracy of excluding infections in the plasma, CSF, and others groups of negative mNGS results were 72.0%, 40.4%, and 30.2%, respectively. The false-negative rates of the CSF and others group were relatively high. The positive impact rates of clinical application in the plasma, CSF, and others groups were 68.0%, 40.4%, and 25.6%, respectively. Three factors, including patient department distribution, admission symptoms, and doctors' judgment of patient infection were used to analyze the reasons for uncertain negative or false-negative results in mNGS. The clinical information analysis of false-negative patients' aims were to reduce the false-negative rate and improve the diagnostic accuracy of mNGS. On the selection of sampling timing in mNGS, within half a month after a patient develops suspected symptoms of infection, the earlier the mNGS test, the higher the true-negative rate.IMPORTANCEThere has been little research carried out on the diagnostic value of negative metagenomics next-generation sequencing (mNGS) results in clinical practice, especially for sterile body fluids. In the present study, plasma negative mNGS results showed the highest diagnostic accuracy for excluding infection. However, the cerebrospinal fluid and other mNGS false-negative rates were 59.6% and 69.8%, respectively. Our findings emphasized the role of negative mNGS results in practical clinical applications and clarified that patients, mNGS sampling time, and doctor's decision making were the key factors for the diagnosis of clinical infections. More attention should be paid to the diagnostic role of mNGS true negatives, the analysis of clinical patterns of false negatives, and improving the diagnostic accuracy of mNGS.
关于宏基因组学下一代测序(mNGS)阴性的文献,已经有很多关于方法学的讨论;因此,我们收集了临床和实验室信息用于回顾性循证研究。我们回顾性分析了150例疑似无菌体液感染患者的mNGS阴性结果,并根据样本类型将其分为血浆组、脑脊液(CSF)组和其他组。根据最终的实验室和临床诊断,mNGS阴性结果的血浆组、CSF组和其他组排除感染的诊断准确率分别为72.0%、40.4%和30.2%。CSF组和其他组的假阴性率相对较高。血浆组、CSF组和其他组临床应用的阳性影响率分别为68.0%、40.4%和25.6%。使用患者科室分布、入院症状和医生对患者感染的判断这三个因素来分析mNGS结果不确定阴性或假阴性的原因。对假阴性患者的临床信息分析旨在降低假阴性率并提高mNGS的诊断准确率。在mNGS采样时间的选择上,患者出现疑似感染症状后的半个月内,mNGS检测越早,真阴性率越高。
重要性
关于宏基因组学下一代测序(mNGS)阴性结果在临床实践中的诊断价值,尤其是对于无菌体液,开展的研究很少。在本研究中,血浆mNGS阴性结果在排除感染方面显示出最高的诊断准确率。然而,脑脊液和其他mNGS的假阴性率分别为59.6%和69.8%。我们的研究结果强调了mNGS阴性结果在实际临床应用中的作用,并阐明患者、mNGS采样时间和医生的决策是临床感染诊断的关键因素。应更加关注mNGS真阴性的诊断作用、假阴性临床模式的分析以及提高mNGS的诊断准确率。